Aeterna hits record low after FDA rejects growth hormone test

November 6, 2014 3:52 PM

1 0

(Reuters) - Canada's Aeterna Zentaris Inc said the U.S. Food and Drug Administration rejected macimorelin, which the drugmaker had hoped would be the first orally administered drug to determine if adults had growth hormone deficiency.

The company's Toronto-listed and U.S.-listed shares both fell by more than half to record lows on Thursday.

Read more

To category page